RBL001/RBL002 Phase I Clinical Trial

Trial status:Study Complete
Trial ID:
RB_0001-01
NCT ID:
NCT01684241
EudraCT ID:
N/A
EU Trial (CTIS) Number:
N/A
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
BioNTech RNA Pharmaceuticals GmbH
Study Complete

Trial Details

Clinical first-in-human dose escalation study evaluating the safety and tolerability of intranodal administration of an RNA-based cancer vaccine targeting two tumor-associated antigens in patients with advanced melanoma

Medical Condition
  • Skin Cancer
    • Trial Drug
  • RBL001/RBL002
    • Phase
    Phase 1
    Type
    Interventional
    Estimated Enrolment
    29
    Estimated Trial Date
    Jun 2012 - May 2015

    Trial Participant Requirements

    Age
    18+ years
    Sex
    Female & Male
    Healthy Volunteers
    No

    Trial Locations

    Location
    Status
    Location
    Medizinische Universität Wien, Abteilung für Dermatologie
    Vienna, Austria, A-1090
    Status
    Location
    Medizinische Fakultät der Universität Duisburg-Essen
    Essen, Germany, 45122
    Status
    Location
    Universtitätsmedizin der Johannes-Gutenberg Universtität
    Mainz, Germany, 55131
    Status
    Location
    Universitätsklinik Mannheim
    Mannheim, Germany
    Status